Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | KIT | P10721 | 4/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4875782 | 0.90 | CA12 (0.48) | ALDH1A1ESR1KITCA1CA2 | |
| SCHEMBL4875769 | 0.90 | HTR6 (0.53) | GAAALDH1A1CA1CA2MEN1 | |
| SCHEMBL4878331 | 0.86 | KIT (0.46) | L3MBTL1KITCA1CA2BRAF | |
| SCHEMBL4876133 | 0.83 | BRAF (0.46) | ALDH1A1KITMEN1KMT2ABRAF | |
| SCHEMBL4879404 | 0.83 | TSHR (0.52) | GAAALDH1A1CA1CA2KMT2A | |
| SCHEMBL4880842 | 0.81 | GAA (0.52) | GAAALDH1A1CA1CA2FFAR4 | |
| SCHEMBL4878313 | 0.79 | SLC22A12 (0.46) | MEN1KMT2A | |
| SCHEMBL4876037 | 0.78 | SLC22A12 (0.62) | — | |
| SCHEMBL4878244 | 0.78 | SGK1 (0.46) | ALDH1A1MEN1KMT2A | |
| SCHEMBL4875699 | 0.77 | ALDH1A1 (0.49) | ALDH1A1KITMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080146599-A1 | Pyrimidine Compounds Having Tie-2 (Tek) Inhibitory Activity | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | US | disclosed |
| US-20080146599-A1 | Pyrimidine Compounds Having Tie-2 (Tek) Inhibitory Activity | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | US | disclosed |
| US-20080146599-A1 | Pyrimidine Compounds Having Tie-2 (Tek) Inhibitory Activity | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | US | disclosed |
| CN-101151261-A | Pyrimidine compounds having tie2 (TEK) inhibitory activity | ASTRAZENECA AB (SE) | 2008-03-26 | — | — | CN | disclosed |
| EP-1846399-A1 | PYRIMIDINE COMPOUNDS HAVING TIE2 (TEK) INHIBITORY ACTIVITY | AstraZeneca AB (SE) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006082371-A1 | PYRIMIDINE COMPOUNDS HAVING TIE2 (TEK) INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146599-A1 | Pyrimidine Compounds Having Tie-2 (Tek) Inhibitory Activity | TIE1, TEK, KDR | L3MBTL1 2524/4885GAA 2230/4885GPR119 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.